866-997-4948(US-Canada Toll Free)

Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2019

Published By :

Global Markets Direct

Published Date : May 2019

Category :

Pharmaceutical

No. of Pages : 81 Pages

Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2019

Summary

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 23 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2019, outlays comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol calcium second messenger system and generates a calcium activated chloride current. mGluR5 plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity.

The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 2 and 11 respectively. Similarly, the universities portfolio in Preclinical stages comprises 7 molecules, respectively. Report covers products from therapy areas Central Nervous System and Genetic Disorders which include indications Anxiety Disorders, Depression, Schizophrenia, Alzheimer's Disease, Autism, Cognitive Impairment Associated With Schizophrenia (CIAS), Dyskinesia, Fragile X Syndrome, Major Depressive Disorder, Alcohol Addiction, Cognitive Disorders, Cognitive Impairment, Dementia, Drug Addiction, Drug-Induced Dyskinesia, Mania, Neurology, Pain, Parkinson's Disease, Rett Syndrome and Spasmodic Torticollis (Cervical Dystonia).

Furthermore, this report also reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
- The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Overview
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Bristol-Myers Squibb Co
Eisai Co Ltd
Eli Lilly and Co
Hua Medicine Shanghai Ltd
Johnson & Johnson
Laboratorio Farmaceutico CT Srl
Novartis AG
Park Active Molecules
Richter Gedeon Nyrt
Sosei Heptares
Sumitomo Dainippon Pharma Co Ltd
Toray Industries Inc
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles
alloswitch-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arbaclofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-952048 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-955829 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-984923 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dipraglurant ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dipraglurant IR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSR-98776 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GET-73 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-0014242 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-46778212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LSN-2814617 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mavoglurant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAM-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize mGlu5 for Rett Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize mGluR5 for Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize mGluR5 for Anxiety - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize MGLUR5 for Anxiety Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0092273 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0431316 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0467558 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Dormant Products
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Discontinued Products
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Product Development Milestones
Featured News & Press Releases
Jan 17, 2019: Experimental drug improves eye gaze behavior in fragile X syndrome
Dec 13, 2018: Sosei Heptares starts new clinical development program - First subject dosed in Phase I study of HTL0014242, a selective mGlu5 negative allosteric modulator in development to treat psychiatric and neurological disorders
Oct 17, 2016: Addex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia
Jun 02, 2016: Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society
Apr 11, 2016: Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers
Mar 15, 2016: Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers
Jan 11, 2016: Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept
Jan 04, 2016: Addex Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinsons Disease
Dec 17, 2015: Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial
Aug 14, 2015: Addex Dipraglurant Demonstrates Anxiolytic- and Antidepressant-like Activity in Multiple Preclinical Models Relevant for Non-Motor Symptoms in Parkinsons Disease
Jul 22, 2015: Addex Dipraglurant Dosed in First Subject in Receptor Occupancy Study in Collaboration with Johns Hopkins University and with Funding from The Michael J. Fox Foundation
Feb 23, 2015: Addex Initiates Dipraglurant Receptor Occupancy Clinical Study in Collaboration with Johns Hopkins University with Funding from The Michael J. Fox Foundation
Jan 19, 2015: Addex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia
Sep 04, 2013: Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1
May 01, 2013: Addex's Dipragluant Demonstrates Dose-dependent mGlu5 Receptor Occupancy In Non-human Primate PET Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Addex Therapeutics Ltd, H1 2019
Pipeline by Bristol-Myers Squibb Co, H1 2019
Pipeline by Eisai Co Ltd, H1 2019
Pipeline by Eli Lilly and Co, H1 2019
Pipeline by Hua Medicine Shanghai Ltd, H1 2019
Pipeline by Johnson & Johnson, H1 2019
Pipeline by Laboratorio Farmaceutico CT Srl, H1 2019
Pipeline by Novartis AG, H1 2019
Pipeline by Park Active Molecules, H1 2019
Pipeline by Richter Gedeon Nyrt, H1 2019
Pipeline by Sosei Heptares, H1 2019
Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2019
Pipeline by Toray Industries Inc, H1 2019
Dormant Products, H1 2019
Dormant Products, H1 2019 (Contd..1), H1 2019
Dormant Products, H1 2019 (Contd..2), H1 2019
Discontinued Products, H1 2019
Discontinued Products, H1 2019 (Contd..1), H1 2019

List of Figures
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *